Kyverna Therapeutics, Inc. 8-K

What Happened
Kyverna Therapeutics, Inc. announced and furnished a press release reporting its business highlights and financial results for the fourth quarter and full year ended December 31, 2025. The company filed the information on Form 8-K (Item 2.02) on March 26, 2026 and attached the press release as Exhibit 99.1.

Key Details

• Filing date: March 26, 2026 (Current Report on Form 8-K).
• Reporting period: fourth quarter and full year ended December 31, 2025.
• Exhibit: Press release dated March 26, 2026 furnished as Exhibit 99.1 to the 8-K.
• Report signed by Marc Grasso, M.D., Chief Financial Officer, on behalf of Kyverna Therapeutics.

Why It Matters
This 8-K makes Kyverna’s quarterly and full-year 2025 earnings and business highlights publicly available—important for investors tracking the company’s financial performance, cash position, and program progress. Retail investors should review the attached press release (Exhibit 99.1) for the specific earnings, revenue, expense, and operational details referenced in the filing.